In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation
PLOS One · 22.04.2026 · 21 (4) · e0339355
DOI: 10.1371/journal.pone.0339355 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 22.04.2026. Verfasst von Neha Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Noida Institute of Engineering and Technology (Pharmacy Institute), Uttar Pradesh, India. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Programmed Cell Death 1 Receptor, Biological Products, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Squamous cell carcinoma (SCC) represents a significant oncological challenge. While immune checkpoint inhibitors targeting PD-1/PD-L1 have revolutionized the treatment of SCC, current monoclonal antibody approaches face limitations, including poor tissue penetration, high costs, and immune-related adverse events in patients. Most existing small-molecule efforts target PD-L1, leaving PD-1/PD-L2 interactions intact and enabling immune escape. This study represents the first systematic identification of natural product-derived direct PD-1 inhibitors, offering broader pathway blockade compared to PD-L1-selective approaches. While current therapeutic limitations highlight the need for alternative methods, this computational study lays a foundation for experimental validation and potential advancement of a drug development pipeline. Through integrated computational screening of 17,967 phytochemicals from the IMPPAT database, we employed consensus molecular docking across seven algorithms, 300-ns molecular dynamics simulations, density functional theory calculations, and comprehensive ADME profiling. IMPHY004834 (Mahuannin D) from Ephedra sinica emerged as a lead compound with exceptional free binding energy, forming stable interactions with key PD-1. Molecular dynamics analysis revealed remarkable stability with consistent RMSD, lowest RMSF, and sustained hydrogen bonding throughout the simulation. The biflavonoid structure exhibits a favorable HOMO-LUMO gap, indicating chemical stability, while ADME profiling confirms drug-like properties, albeit requiring parenteral administration due to low GI absorption. This work establishes the first evidence for Mahuannin D’s PD-1 inhibitory mechanism, which was previously known only for its cytotoxic effects. It provides a validated computational framework for discovering natural product-based immune checkpoint inhibitors with superior pathway coverage compared to existing PD-L1-selective therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Noida Institute of Engineering and Technology (Pharmacy Institute), Uttar Pradesh, India.
- Ram-Eesh Institute of Vocational and Technical Education, Uttar Pradesh, India.
- Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi-, India.
ORCID-Profile: Abhijit Debnath
Zitieren
APA
Sharma, N., Debnath, A., Mazumder, R., Rai, P., & Singh, R. K. (2026). In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation. PLOS One, 21(4), e0339355. https://doi.org/10.1371/journal.pone.0339355
Vancouver
Sharma N, Debnath A, Mazumder R, Rai P, Singh RK. In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation. PLOS One. 2026;21(4):e0339355. doi:10.1371/journal.pone.0339355
BibTeX
@article{Sharma2026,
author = {Sharma, Neha and Debnath, Abhijit and Mazumder, Rupa and Rai, Pallavi and Singh, Rajesh Kumar},
title = {In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0339355},
doi = {10.1371/journal.pone.0339355}
}
EUVIMED